Company intelligence / Profile preview

GABAeron, Inc.

San Francisco, California, United Statesgabaeron.com ↗

Ownership: Private
Development stage: Preclinical

Overview

GABAeron has presented promising preclinical data showing that transplantation of human iPSC-derived interneuron progenitors can restore learning and memory in mouse models of Alzheimer’s disease. The company is advancing its first-in-class cell therapy candidate toward IND-enabling studies with the goal of entering clinical trials for AD. No active clinical trials are currently listed on ClinicalTrials.gov as of May 2025.

Therapeutic areas: Neurology
Modalities: Induced pluripotent stem cell (iPSC)-derived cell therapySmall molecules
Industry: Biotech

Drug pipeline

1 asset

GABAeron iPSC-derived GABAergic interneuron progenitor cells

Preclinical

Partnerships

Zhongzhi Pharmaceutical Holdings Ltd. ($3M Series A investment, Dec. 2024)

Beyond the preview

Go deeper on GABAeron, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GABAeron, Inc..

Explore the full profile